DelSiTech And Bayer Partner To Develop Innovative Drug Delivery Technology For Ophthalmology
On the picture:
DelSiTech Ltd, a Finnish drug delivery technology and drug development company, and Bayer have signed a Collaboration and Technology Licence Agreement for the worldwide application of DelSiTech’s Silica Matrix drug delivery platform to a number of Bayer’s compounds in ophthalmology. Read more.
DelSiTech Ltd., located in Turku, Finland, develops and commercializes its proprietary biodegradable silica based drug delivery technology. The Company collaborates with a number of pharma and biotech companies globally and works with its partners to turn their product ideas into novel drug products.
20 September 2018
Bioagora 2018 (Copenhagen)
19 September 2018
STZ OcuTox: Drug development know-how
12 September 2018
Good industry performance lifted spirits in the HealthBIO conference